Development of a novel multiepitope vaccine against Menangle virus (MenV) using in-silico approaches by targeting its transmembrane proteins

Menangle Virus (MenV) is a zoonotic pathogenic virus that can penetrate humans, causing infection in them. It is an essential threat to public health due to the possibility of cross-species transmissions. Traditional vaccine development methods are time-consuming and resource-intensive, highlighting the need for innovative approaches. This study uses computational techniques to develop a multiepitope vaccine for MenV. We employed in silico tools to find potential B-cell, T-cell, and MHC-binding epitopes in the viral proteome. To ensure their safety and efficacy, these epitopes were evaluated for antigenicity, allergenicity, and toxicity. The selected epitopes were assembled into a multiepitope construct optimized for molecular stability and immunogenicity. Studies of molecular docking and MD simulations were considered to assess the interaction of vaccine candidates with human receptors, indicating a strong immune response. The goal of developing this vaccine is to prepare for potential future outbreaks. This in-silico vaccine design proposes a promising, efficient path to developing effective preventative measures against MenV, potentially expediting vaccine production and contributing to world health security.